Observation of the Efficacy and Safety of TKI Class Anti-angiogenic Drugs in the Treatment of Advanced Breast Cancer
Objective:To evaluate the efficacy and safety of tyrosine kinase inhibitors(TKI)anti-angiogenic drugs in patients with advanced breast cancer.Method:A retrospective analysis was conducted on 102 advanced breast cancer patients treated at Jilin Cancer Hospital from June 2020 to July 2022.Patients received TKI anti-angiogenic drugs were designated as the observation group(41 cases),while those received albumin-bound paclitaxel were selected as the control group(61 cases).The objective response rate(ORR),clinical benefit rate(CBR),progression-free survival(PFS),overall survival(OS)were compared;serum tumor markers[carcinoembryonic antigen(CEA),cancer antigen(CA)153,tissue polypeptide-specific antigen(TPS)]were measured;adverse reactions were classified and recorded according to CTCAE 4.0 criteria.Result:The ORR of the observation group was 34.15%,and the CBR was 58.54%,PFS was(11.51±1.64)months,and OS was(28.45±4.84)months.Post-treatment,the levels of CEA,CA153 and TPS in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in grade 1,2,3,and 4 adverse reactions between the observation and control groups(P>0.05).Conclusion:TKI class anti-angiogenic drugs demonstrate certain efficacy in the treatment of advanced breast cancer,with a high disease control rate and acceptable safety profile.However,given the lack of complete remission cases,future research should further explore their combination with other treatment modalities to improve the overall treatment outcomes in advanced breast cancer patients.
Advanced breast cancerTyrosine kinase inhibitorsAnti-angiogenic drugsProgression-free survivalAdverse reactions
国家科技期刊平台
NSTL
万方数据
